About
Immune Pharmaceuticals Inc is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By neutralizing eotaxin-1, bertilimumab may prevent the migration of eosinophils and other cells, thereby helping to relieve associated inflammatory conditions. Immune Pharmaceuticals is currently conducting two phase-2 clinical trials to test bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis. Bertilimumab may also have applications in other conditions including atopic dermatitis, asthma, and other eosinophil-mediated diseases.